EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Association between PLVAP downregulation and increased lymphocyte infiltration in newly diagnosed glioblastoma treated with bevacizumab

Hiroaki Matsuzaki, Shukang Zhao, Yoshihiro Komohara, Cheng Pan, Rin Yamada, Daiki Yoshii, Yukio Fujiwara, Hiromu Yano, Ai Iwauchi, Nei Fukasawa, Masayuki Shimoda, Akitake Mukasa und 1 weitere

Brain Tumor Pathology · 20.07.2026

DOI: 10.1007/s10014-026-00546-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brain Tumor Pathology, online erschienen am 20.07.2026. Verfasst von Hiroaki Matsuzaki und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cell Pathology, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto, 860-8556, Japan. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kumamoto University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioblastoma (GBM) is a highly lethal brain tumor resistant to immunotherapy such as immune checkpoint inhibitors, partly because of an immunosuppressive tumor microenvironment and blood–brain barrier (BBB) dysfunction. Although bevacizumab can remodel the tumor vasculature, the relationship between BBB-related vascular changes and immune cell infiltration in GBM remains poorly understood. We analyzed human isocitrate dehydrogenase ( IDH )-wildtype GBM tissues obtained after bevacizumab administration. Immunohistochemistry was performed for CD34 and plasmalemma vesicle-associated protein (PLVAP/PV-1), an endothelial marker associated with BBB disruption. Infiltrating T cells (CD3, CD8) and tumor-associated macrophages/microglia (TAMs; CD163) were also examined. PLVAP was broadly expressed in tumor vessels of untreated GBM and significantly reduced after bevacizumab administration, with marked downregulation in 3 of 10 treated cases. Among the 10 treated cases, significant increases in T-cell and cytotoxic T-lymphocyte infiltration were seen in PLVAP-low GBM compared with PLVAP-high GBM. TAM density did not differ significantly between groups but tended to be higher in the PLVAP-low group. These findings suggest that the bevacizumab-associated reduction of PLVAP expression is linked to increased T-cell infiltration in a subset of GBM cases. PLVAP may serve as an auxiliary histological marker for evaluating bevacizumab-related vascular/BBB remodeling in clinical specimens.

Schlagwörter

Stichwörter der Autor:innen

Blood brain barrierGlioblastomaPLVAPPV-1Tumor-associated macrophage/microgliaTumor-infiltrating lymphocytes

Autor:innen und Institutionen

  • Department of Cell Pathology, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto, 860-8556, Japan.
  • Department of Neurosurgery, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto, 860-8556, Japan.
  • Department of Cell Pathology, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto, 860-8556, Japan. ycomo@kumamoto-u.ac.jp.
  • Department of Tumor Pathology, Graduate School of Health Sciences, Kumamoto University, 4-24-1 Kuhonji, Chuo-ku, Kumamoto, 862-0976, Japan.
  • Department of Pathology, Jikei University School of Medicine, 3‑25‑8 Nishi‑Shinbashi, Minato‑ku, Tokyo, 105‑8461, Japan.
  • Department of Neurosurgery, Jikei University School of Medicine, 3‑25‑8 Nishi‑Shinbashi, Minato‑ku, Tokyo, 105‑8461, Japan.

Förderung

  • Kumamoto University

Zitieren

APA

Matsuzaki, H., Zhao, S., Komohara, Y., Pan, C., Yamada, R., Yoshii, D., Fujiwara, Y., Yano, H., Iwauchi, A., Fukasawa, N., Shimoda, M., Mukasa, A., & Tanaka, T. (2026). Association between PLVAP downregulation and increased lymphocyte infiltration in newly diagnosed glioblastoma treated with bevacizumab. Brain Tumor Pathology. https://doi.org/10.1007/s10014-026-00546-2

Vancouver

Matsuzaki H, Zhao S, Komohara Y, Pan C, Yamada R, Yoshii D, et al. Association between PLVAP downregulation and increased lymphocyte infiltration in newly diagnosed glioblastoma treated with bevacizumab. Brain Tumor Pathology. 2026. doi:10.1007/s10014-026-00546-2

BibTeX
@article{Matsuzaki2026,
  author = {Matsuzaki, Hiroaki and Zhao, Shukang and Komohara, Yoshihiro and Pan, Cheng and Yamada, Rin and Yoshii, Daiki and Fujiwara, Yukio and Yano, Hiromu and Iwauchi, Ai and Fukasawa, Nei and Shimoda, Masayuki and Mukasa, Akitake and Tanaka, Toshihide},
  title = {Association between PLVAP downregulation and increased lymphocyte infiltration in newly diagnosed glioblastoma treated with bevacizumab},
  journal = {Brain Tumor Pathology},
  year = {2026},
  doi = {10.1007/s10014-026-00546-2}
}
Kostenlos starten →